Patents by Inventor Patrick B. O'Donnell

Patrick B. O'Donnell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating proliferative diseases
    Patent number: 9555040
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: January 31, 2017
    Assignee: Ambit Biosciences Corporation
    Inventors: Robert E. Corringham, Joyce K. James, Patrick B. O'Donnell
  • METHODS OF TREATING PROLIFERATIVE DISEASES
    Publication number: 20160051557
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Application
    Filed: September 17, 2014
    Publication date: February 25, 2016
    Inventors: Robert E. Corringham, Joyce K. James, Patrick B. O'Donnell
  • Methods of treating proliferative diseases
    Patent number: 8865710
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Grant
    Filed: May 14, 2010
    Date of Patent: October 21, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Robert E. Corringham, Patrick B. O'Donnell, Joyce K. James
  • Hydrobromide salts of a pyrazolylaminoquinazoline
    Patent number: 8633209
    Abstract: Provided herein are hydrobromide salts of a pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a proliferative disease.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: January 21, 2014
    Assignee: Ambit Biosciences Corporation
    Inventors: Timothy David Gross, Patrick B. O'Donnell
  • METHODS OF TREATING PROLIFERATIVE DISEASES
    Publication number: 20120258081
    Abstract: Provided herein are methods of administering N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt or solvate thereof, to human patients, including a specific patient population. Specifically, dosing, dosing schedules or dosing regimens are provided herein. Methods of treating proliferative diseases or FLT-3 mediated diseases in humans are also provided.
    Type: Application
    Filed: May 14, 2010
    Publication date: October 11, 2012
    Applicant: AMBIT BIOSCIENCES CORPORATION
    Inventors: Robert E. Corringham, Patrick B. O'Donnell, Joyce K. James
  • HYDROBROMIDE SALTS OF A PYRAZOLYLAMINOQUINAZOLINE
    Publication number: 20120053195
    Abstract: Provided herein are hydrobromide salts of a pyrazolylaminoquinazoline, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating a proliferative disease.
    Type: Application
    Filed: August 31, 2011
    Publication date: March 1, 2012
    Applicant: AMBIT BIOSCIENCES CORP.
    Inventors: Timothy David Gross, Patrick B. O'Donnell
  • Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-?]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
    Patent number: 6958342
    Abstract: Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-?]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: October 25, 2005
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: William J. Thiele, Patrick B. O'Donnell
  • Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-alpha]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
    Publication number: 20030199524
    Abstract: Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided.
    Type: Application
    Filed: January 29, 2003
    Publication date: October 23, 2003
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: William J. Thiele, Patrick B. O'Donnell
  • Polymorphs of N-methyl-N-(3-{3-[2- thienylcarbonyl]-pyrazol-[1,5-&agr;]- pyrimidin-9-yl}phenyl)acetamide and compositions and methods related thereto
    Patent number: 6544999
    Abstract: Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided.
    Type: Grant
    Filed: October 16, 2001
    Date of Patent: April 8, 2003
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: William J. Thiele, Patrick B. O'Donnell
  • Polymorphs of N-methyl-N-(3-{3-[2- thienylcarbonyl]-pyrazol-[1,5-alpha]- pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
    Publication number: 20020107256
    Abstract: Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided.
    Type: Application
    Filed: October 16, 2001
    Publication date: August 8, 2002
    Applicant: Neurocrine Biosciences, Inc.
    Inventors: William J. Thiele, Patrick B. O'Donnell
  • Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide and compositions and methods related thereto
    Patent number: 6384221
    Abstract: Polymorphs of N-methyl-N-(3-{3-[2-thienylcarbonyl]-pyrazol-[1,5-&agr;]-pyrimidin-7-yl}phenyl)acetamide (Compound 1), and use of the same as a sedative-hypnotic, anxiolytic, anticonvulsant, and skeletal muscle relaxant agent. Processes for making the same, as well as related compositions and methods are also disclosed, particularly with regard to treatment of insomnia. A polymorph Form I possessing exception physical and heat stability is provided.
    Type: Grant
    Filed: September 1, 2000
    Date of Patent: May 7, 2002
    Assignee: Neurocrine Biosciences, Inc.
    Inventors: William Jay Thiele, Patrick B. O'Donnell